The MADE in America Act is essential for the pharmaceutical industry

The past two years are ripe with many lessons. From education to access to health care to supply chains, America has had to review and reorganize the way it works, learns and does business. We have also been faced with the challenges of our global interdependence.

While much good can come from our interdependence, there are indeed risks that come with it. Many American industries have realized that we have become too dependent on overseas manufacturing. This is especially true when it comes to the pharmaceutical industry.

When supply chains are down and global shipping is at a standstill, waiting for decorations, toys and other consumer goods can be frustrating. But when it comes to prescription drugs, the wait can be life-threatening.

Before COVID-19 hit, many in our industry knew that our reliance on foreign countries for so many critical links in the pharmaceutical supply chain was an impending disaster.

An estimated 80% of the active pharmaceutical ingredients used to create many of the drugs Americans rely on come from China and India, along with a few other countries. When these governments closed factories and borders, getting these needed ingredients became a challenge, crippling supply chains and becoming a public health emergency here at home.

That’s why last week the Biden administration signed a executive order to launch a national biotechnology and biomanufacturing initiative. The goal is to increase our domestic biomanufacturing capacity to compete more effectively with foreign manufacturers and reduce our dependence on them.

This week, bioscience leaders from across Texas gathered in Irving to collaborate on ways to continue to grow North Texas’ life sciences industry. Our state is a leader in the national biopharmaceutical industry, attracting investors and innovators who want to continue to build on a track record of innovation and discovery.

But our industry needs the right policy and regulatory environment to continue to thrive and grow so we can stay competitive and develop more manufacturing capacity here in the Lone Star State.

US legislators must encourage and encourage the domestic production of pharmaceuticals and their components. And the good news is that there is currently a vehicle in Congress that would allow them to do just that. The legislation, the Manufacturing Active Pharmaceutical Ingredients, Drugs and Excipients (MADE) Act in Americaenjoys bipartisan support in both the House and the Senate, a sign of the importance of this bill.

The bill would encourage domestic manufacturing and improve and streamline Food and Drug Administration processes to help strengthen domestic manufacturing.

Domestic production is good for our physical health, and it’s good for our economic health. Life science jobs are good, well-paying jobs, and creating more of them here in the Lone Star State will only enhance Texas’ reputation as a bioscience leader.

In the coming weeks, Congress has an opportunity to act on the MADE in America Act as part of its broader efforts to pass the reauthorization of the Prescription Drug User Fee Act, a bill essential legislation to fund the FDA and help patients access treatments as quickly as possible. possible. The current authorization of this law will expire on September 30.

U.S. Representative Michael Burgess, R-Lake Dallas, is a House health care leader. His support for this legislation will ensure that we can bring more manufacturing to Texas, help balance our supply chain, and ensure that we can do our part to compete with China. On behalf of the Texas life sciences industry, we are asking them to support this legislation.

Victoria Ford is President and CEO of Texas Healthcare & Bioscience Institute. She wrote this column for The Dallas Morning News.

We welcome your thoughts in a letter to the editor. Consult the instructions and drop your letter here.